Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2

Nature·Oct 1

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Researchers are exploring t-cell adhesion molecules as potential targets for cancer immunotherapy, with a focus on cd226 and cd2. This approach may offer new possibilities for treating cancer. The molecules cd226 and cd2 are being specifically examined for their potential role in immunotherapy.

Full coverage

“Brake” and “accelerator”: revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy

Frontiers·Jan 15

The Tumor-suppressive role of CNTNAP2 in glioma: Dual regulation of the NDN-ERK axis and M2 macrophage polarization | Cancer Gene Therapy

Nature·Jun 10

Revisiting the past in light of current knowledge on γδ T cells in leishmaniasis

Frontiers·Feb 26

Nuclear envelope proteins in cancer: revisiting the significance of LEM-domain proteins

Frontiers·Mar 27

Revisiting the PD-1 pathway

Science | AAAS·Sep 3

Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma

Science Partner Journals·Jun 24

CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation

Nature·Jul 4

Revisiting old drugs and drug combinations for polycythemia vera and related neoplasms

Frontiers·Mar 9

View original report at Nature ↗

Fetching the latest headlines…